Table 1. Numbers and annual crude rates per 100 000 (95% CI), median ages at diagnosis: Haematological Malignancy Research Network (HMRN), 2004–2009.
| Total | Median age at diagnosis |
Annual rates (95% CI) per 100 000
|
Sex-rate ratio: male/female | |||
|---|---|---|---|---|---|---|
| Neoplasm (common abbreviation/synonym) | diagnoses | (years) | Total | Males | Females | (95% CI) |
| All diagnoses | 10 729 | 70.6 | 60.1 (58.9–61.2) | 68.5 (66.8–70.3) | 52.1(50.7–53.6) | 1.31 (1.26–1.36) |
| Total myeloid | 2706 | 72.0 | 15.1 (14.6–15.7) | 16.9 (16.0–17.8) | 13.5 (12.8–14.3) | 1.25 (1.16–1.35) |
| Chronic myelogenous leukaemia (CML) | 165 | 59.1 | 0.9 (0.8–1.1) | 1.1 (0.9–1.4) | 0.7 (0.6–0.9) | 1.48 (1.07–2.05) |
| Primary myelofibrosis | 73 | 73.0 | 0.4 (0.3–0.5) | 0.6 (0.4–0.7) | 0.3 (0.2–0.4) | 2.04 (1.24–3.46) |
| Chronic myeloproliferative neoplasms (MPN) | 961 | 71.1 | 5.4 (5.0–5.7) | 4.8 (4.3–5.3) | 6.0 (5.5–6.5) | 0.80 (0.70–0.91) |
| Chronic myelomonocytic leukaemia (CMML) | 96 | 76.1 | 0.6 (0.5–0.7) | 0.8 (0.6–1.0) | 0.4 (0.3–0.5) | 2.10 (1.38–3.25) |
| Myelodysplastic syndromes (MDS) | 653 | 76.1 | 3.7 (3.4–3.9) | 5.0 (4.5–5.5) | 2.4 (2.1–2.7) | 2.09 (1.78–2.48) |
| Acute myeloid leukaemias (AML) | 717 | 68.7 | 4.0 (3.7–4.3) | 4.5 (4.0–4.9) | 3.6 (3.2–4.0) | 1.25 (1.07–1.45) |
| Total lymphoid | 8023 | 70.1 | 44.9 (44.0–45.9) | 51.6 (50.1–53.2) | 38.6 (37.4–39.9) | 1.34 (1.28–1.40) |
| Precursor B-lymphoblastic leukaemia (B-ALL) | 167 | 12.7 | 0.9 (0.8–1.1) | 1.0 (0.8–1.2) | 0.9 (0.7–1.1) | 1.13 (0.82–1.55) |
| Precursor T-lymphoblastic leukaemia (T-ALL) | 50 | 18.5 | 0.3 (0.2–0.4) | 0.4 (0.4–0.5) | 0.2 (0.1–0.3) | 1.89 (1.03–3.58) |
| Monoclonal B-cell lymphocytosis (MBL) | 445 | 71.7 | 2.5 (2.3–2.7) | 2.7 (2.4–3.1) | 2.3 (2.0–2.6) | 1.18 (0.98–1.43) |
| Chronic lymphocytic leukaemia (CLL) | 1145 | 71.6 | 6.4 (6.0–6.8) | 8.1 (7.5–8.7) | 4.8 (4.4–5.3) | 1.69 (1.50–1.91) |
| Marginal zone lymphomas (MZL) | 530 | 71.5 | 3.0 (2.7–3.2) | 3.4 (3.1–3.9) | 2.5 (2.2–2.9) | 1.37 (1.15–1.63) |
| Hairy-cell leukaemia (HCL) | 55 | 65.7 | 0.3 (0.2–0.4) | 0.5 (0.3–0.7) | 0.1 (0.1–0.2) | 3.44 (1.81–6.98) |
| Monoclonal gammopathy of undetermined significance (MGUS) | 1135 | 72.2 | 6.4 (6.0–6.7) | 7.4 (6.8–8.0) | 5.4 (4.9–5.9) | 1.38 (1.23–1.56) |
| Plasma cell myeloma (multiple myeloma) | 1127 | 73.0 | 6.3 (5.9–6.7) | 7.5 (6.9–8.1) | 5.2 (4.8–5.7) | 1.43 (1.27–1.61) |
| Plasmacytoma | 99 | 69.2 | 0.6 (0.5–0.7) | 0.8 (0.6–1.0) | 0.4 (0.3–0.5) | 2.03 (1.32–3.18) |
| Follicular lymphomas (FL) | 547 | 64.6 | 3.1 (2.8–3.3) | 2.9 (2.6–3.3) | 3.2 (2.8–3.6) | 0.92 (0.77–1.09) |
| Mantle-cell lymphoma | 144 | 74.0 | 0.8 (0.7–0.9) | 1.1 (0.9–1.3) | 0.6 (0.4–0.7) | 1.88 (1.33–2.70) |
| Diffuse large B-cell lymphomas (DLBCL) | 1417 | 70.4 | 7.9 (7.5–8.4) | 8.4 (7.8–9.1) | 7.5 (6.9–8.1) | 1.13 (1.01–1.26) |
| Burkitt lymphoma (BL) | 66 | 52.2 | 0.4 (0.3–0.5) | 0.6 (0.4–0.8) | 0.2 (0.1–0.3) | 3.33 (1.86–6.26) |
| Lymphoproliferative disorders NOS (LPD) | 330 | 76.9 | 1.8 (1.7–2.3) | 2.0 (1.7–2.3) | 1.7 (1.4–2.0) | 1.19 (0.95–1.87) |
| T-cell leukaemia | 64 | 74.7 | 0.4 (0.3–0.5) | 0.3 (0.2–0.5) | 0.4 (0.3–0.5) | 0.94 (0.56–1.58) |
| T-cell lymphoma | 188 | 65.7 | 1.1 (0.9–1.2) | 1.2 (1.0–1.5) | 0.9 (0.7–1.1) | 1.44 (1.07–1.94) |
| Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) | 50 | 42.9 | 0.3 (0.2–0.4) | 0.4 (0.4–0.5) | 0.2 (0.1–0.3) | 2.07 (1.12–3.95) |
| Classical Hodgkin lymphoma (CHL) | 464 | 41.2 | 2.6 (2.4–2.8) | 2.9 (2.5–3.3) | 2.3 (2.0–2.7) | 1.23 (1.02–1.49) |
Abbreviations: CI=confidence interval; NOS=not otherwise specified.